College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates; Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates; Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33326, USA.
Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
J Control Release. 2022 Dec;352:726-746. doi: 10.1016/j.jconrel.2022.10.059. Epub 2022 Nov 10.
Owing to their biological diversity, high potency, good tolerability, low immunogenicity, site-specific activity, and great efficacy, macromolecular drugs (i.e., proteins and peptides, antibodies, hormones, nucleic acids, vaccines, etc.) are extensively used as diagnostics, prophylactics, and therapeutics in various diseases. To overcome drawbacks associated with parenteral (invasive) delivery of macromolecules as well as to preserve their therapeutic integrity, oromucosal route (sublingual and buccal) has been proven efficient alternate port of delivery. This review aims to summarize challenges associated with oromucosal route and overtime developments in conventional delivery systems with special emphasis on most recent delivery strategies. Over the past few decades, significant efforts have been made for improving the oromucosal absorption of macromolecules by employing chemical penetration enhancers (CPE), enzyme inhibitors, chemical modification of drug structure (i.e., lipidation, PEGylation, etc.), and mucoadhesive materials in the form of buccal tablets, films (or patches), sprays, fast disintegrating tablets, and microneedles. Adaptation of adjunct strategies (e.g., iontophoresis in conjunction with CPE) has shown significant improvement in oromucosal absorption of macromolecules; however, these approaches were also associated with many drawbacks. To overcome these shortcomings and to further improve therapeutic outcomes, specialized delivery devices called "hybrid nanosystems" have been designed in recent times. This newer intervention showed promising potential for promoting oromucosal absorption and absolute bioavailability of macromolecules along with improved thermostability (cold chain free storage), enabling self-administration, site-specific activity, improving therapeutic efficacy and patient compliance. We anticipate that tailoring of hybrid nanosystems to clinical trials as well as establishing their short- and long-term safety profile would substantiate their therapeutic value as pharmaceutical devices for oromucosal delivery of macromolecules.
由于其生物多样性、高功效、良好的耐受性、低免疫原性、特异性活性和显著疗效,大分子药物(即蛋白质和肽、抗体、激素、核酸、疫苗等)被广泛用作各种疾病的诊断试剂、预防药物和治疗药物。为了克服大分子药物经皮(侵入性)给药的缺点,保持其治疗的完整性,经口黏膜(舌下和颊黏膜)给药途径已被证明是一种有效的替代给药途径。本综述旨在总结经口黏膜给药途径相关的挑战,以及常规给药系统的发展历程,特别强调最近的给药策略。在过去的几十年中,人们为了提高大分子药物的经口黏膜吸收,付出了巨大努力,采用了化学渗透增强剂(CPE)、酶抑制剂、药物结构化学修饰(即脂质化、PEG 化等)和黏膜黏附材料,制成了颊片剂、膜(或贴剂)、喷雾剂、速崩片和微针。联合策略(如 CPE 联合离子电渗)的应用显著提高了大分子药物的经口黏膜吸收;然而,这些方法也存在许多缺点。为了克服这些缺点,进一步提高治疗效果,最近设计了一种称为“混合纳米系统”的辅助治疗设备。这种新型干预措施显示出了促进大分子药物经口黏膜吸收和绝对生物利用度的巨大潜力,同时提高了热稳定性(无需冷链储存),实现了自我给药、靶向活性、改善治疗效果和提高患者依从性。我们预计,将混合纳米系统定制为临床试验,并建立其短期和长期安全性概况,将证实其作为大分子药物经口黏膜给药的药物输送装置的治疗价值。